Skip to content

V-A ECMO AUTO Mode Registry

Abiomed Impella V-A ECMO AUTO Mode - Observational Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05759377
Enrollment
46
Registered
2023-03-08
Start date
2023-10-11
Completion date
2025-06-03
Last updated
2025-07-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure

Brief summary

Abiomed Impella V-A ECMO AUTO Mode - Observational Study

Detailed description

The overall objective of this study is to collect data during routine Impella usage in an ECpella setting to analyze and assess potential clinical effects, usability, and ease of use of an automated Impella mode to run in conjunction with a VA ECMO system for continued assessment and development of the underlying algorithms in different clinical settings. The primary objective is thus the collection of clinical events to serve as a database for an in-silico post-hoc analysis of the V-A ECMO AUTO Mode algorithm for the Impella pump. This is accompanied by a secondary objective assessing usability, confirming the user friendliness and ease of use by collection of user experience and insights through a questionnaire and data on alarms and manual user interaction with the AIC out of the operational console data.

Interventions

DEVICEV-A ECMO AUTO Mode algorithm

The clinical effects of utilizing the V-A ECMO AUTO Mode in parallel with VA ECMO treatment shall be assessed in different clinical settings. For this, a set of relevant clinical situations and findings (events) has been defined as trigger points where technical (via AIC) and clinical data shall be collected, linked, and analyzed. This assessment of raw data is important to further develop and adapt the software.

Sponsors

Abiomed Inc.
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

* Patients with ongoing or planned ECpella therapy

Exclusion criteria

* Age \< 18 years * Treatment with other than VA ECMO setup * Treatment with Impella CP® heart pump only

Design outcomes

Primary

MeasureTime frameDescription
Gather clinical event dataUntil one of the devices is permanently weaned, on average 5 daysCollection of clinical events to serve as a database for an in-silico post-hoc analysis of the V-A ECMO AUTO Mode algorithm
Usability assessmentUntil study completion, an average of 1 yearConfirmation of usability and ease of use by collection of user data and operational console data

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026